Ligand

About Ligand

Ligand-owned, Captisol® was invented in 1990 by scientists at the University of Kansas Higuchi Biosciences Center for use in drug development and formulation.

The Captisol® technology is used to address the limitations of currently marketed drugs. FDA-approved, Captisol-enabled® medications are marketed by: Pfizer, Bristol-Myers Squibb and Baxter International. Captisol® also has License and Supply Agreements (LSAs) in place with a number of pharmaceutical companies worldwide with Captisol-enabled® product candidates. Routes of administration investigated include parenteral, oral, ophthalmic, nasal, topical, oral, and inhalation.

Captisol® is a patent protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).

  • US
  • 2017
    On CPHI since
Company types
Contract Service
Contact info
  • 2029 Becker Drive, Suite 217, Lawrence, KS, United States
Meet us at

CPHI North America 2023

Pennsylvania Convention Center, PHL
April 25 - 27, 2023

Products from Ligand (1)

  • Captisol

    Product Captisol

    Captisol® is a patent protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).



Ligand Resources (1)